Evidence map›Paper›PMID 26085147›Full record

ArticleJournal of virology2015

Biology of Zika Virus Infection in Human Skin Cells.

Rodolphe Hamel, Ophélie Dejarnac, Sineewanlaya Wichit, Peeraya Ekchariyawat, Aymeric Neyret, Natthanej Luplertlop, Manuel Perera-Lecoin, Pornapat Surasombatpattana, Loïc Talignani, Frédéric Thomas and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 708 papers.

0numbers the graph read from it
0cells of the map it votes in
708citing papers in PubMed
172.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

708 citing papers in PubMed, 1,198 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

648 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Rodolphe HamelLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France.
Ophélie DejarnacINSERM, U944, Laboratoire de Pathologie et Virologie Moléculaire, Paris, France.
Sineewanlaya WichitLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France.
Peeraya EkchariyawatLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France.
Aymeric NeyretCentre d'Étude d'Agents Pathogènes et Biotechnologies pour la Santé, CNRS-UMR 5236/UM, Montpellier, France.
Natthanej LuplertlopDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Manuel Perera-LecoinLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France.
Pornapat SurasombatpattanaPathology Department, Prince of Songkla University, Songkla, Thailand.
Loïc TalignaniLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France.
Frédéric ThomasLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France.
Van-Mai Cao-LormeauInstitut Louis Malardé, Papeete, Tahiti, French Polynesia.
Valérie ChoumetEnvironment and Infectious Risks Unit, Institut Pasteur, Paris, France.
Laurence BriantCentre d'Étude d'Agents Pathogènes et Biotechnologies pour la Santé, CNRS-UMR 5236/UM, Montpellier, France.
Philippe DesprèsDépartement Infections et Epidémiologie, Institut Pasteur, Paris, France, and UMR PIMIT (I2T Team), Université de La Réunion, INSERM U1187, CNRS 9192, IRD 249, GIP-CYROI, Saint Clotilde, La Réunion, France.
Ali AmaraINSERM, U944, Laboratoire de Pathologie et Virologie Moléculaire, Paris, France.
Hans YsselCentre d'Immunologie et des Maladies Infectieuses, INSERM, U1135, Sorbonne Universités, UPMC, APHP Hôpital Pitié-Salpêtrière, Paris, France.
Dorothée MisséLaboratoire MIVEGEC, UMR 224 IRD/CNRS/UM, Montpellier, France dorothee.misse@ird.fr.
Institut de Recherche pour le Développement · FRInserm · FRCentre National de la Recherche Scientifique · FRCentre d’études d’agents Pathogènes et Biotechnologies Pour la Santé · FRInstitut Louis Malardé · PFInstitut Pasteur · FRMahidol Oxford Tropical Medicine Research Unit · THPrince of Songkla University · THSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledZika virus (ZIKV) is an emerging arbovirus of the Flaviviridae family, which includes dengue, West Nile, yellow fever, and Japanese encephalitis viruses, that causes a mosquito-borne disease transmitted by the Aedes genus, with recent outbreaks in the South Pacific. Here we examine the importance of human skin in the entry of ZIKV and its contribution to the induction of antiviral immune responses. We show that human dermal fibroblasts, epidermal keratinocytes, and immature dendritic cells are permissive to the most recent ZIKV isolate, responsible for the epidemic in French Polynesia. Several entry and/or adhesion factors, including DC-SIGN, AXL, Tyro3, and, to a lesser extent, TIM-1, permitted ZIKV entry, with a major role for the TAM receptor AXL. The ZIKV permissiveness of human skin fibroblasts was confirmed by the use of a neutralizing antibody and specific RNA silencing. ZIKV induced the transcription of Toll-like receptor 3 (TLR3), RIG-I, and MDA5, as well as several interferon-stimulated genes, including OAS2, ISG15, and MX1, characterized by strongly enhanced beta interferon gene expression. ZIKV was found to be sensitive to the antiviral effects of both type I and type II interferons. Finally, infection of skin fibroblasts resulted in the formation of autophagosomes, whose presence was associated with enhanced viral replication, as shown by the use of Torin 1, a chemical inducer of autophagy, and the specific autophagy inhibitor 3-methyladenine. The results presented herein permit us to gain further insight into the biology of ZIKV and to devise strategies aiming to interfere with the pathology caused by this emerging flavivirus. IMPORTANCE: Zika virus (ZIKV) is an arbovirus belonging to the Flaviviridae family. Vector-mediated transmission of ZIKV is initiated when a blood-feeding female Aedes mosquito injects the virus into the skin of its mammalian host, followed by infection of permissive cells via specific receptors. Indeed, skin immune cells, including dermal fibroblasts, epidermal keratinocytes, and immature dendritic cells, were all found to be permissive to ZIKV infection. The results also show a major role for the phosphatidylserine receptor AXL as a ZIKV entry receptor and for cellular autophagy in enhancing ZIKV replication in permissive cells. ZIKV replication leads to activation of an antiviral innate immune response and the production of type I interferons in infected cells. Taken together, these results provide the first general insights into the interaction between ZIKV and its mammalian host.

Indexed as

Virus InternalizationVirus ReplicationAedesAnimalsAutophagyAxl Receptor Tyrosine KinaseCell Adhesion MoleculesCells, CulturedChlorocebus aethiopsCytokinesDC-Specific ICAM-3 Grabbing NonintegrinDEAD Box Protein 58DEAD-box RNA HelicasesDendritic CellsFibroblastsFlaviviridaeAxl Receptor Tyrosine KinaseCell Adhesion MoleculesCytokinesDC-Specific ICAM-3 Grabbing NonintegrinDEAD Box Protein 58DEAD-box RNA HelicasesHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1IFIH1 protein, humanInterferon-betaInterferon-Induced Helicase, IFIH1ISG15 protein, humanLectins, C-TypeMembrane GlycoproteinsMX1 protein, humanMyxovirus Resistance ProteinsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesReceptors, Cell SurfaceReceptors, ImmunologicReceptors, VirusRIGI protein, humanRNA, Small InterferingTLR3 protein, humanTLR7 protein, humanToll-Like Receptor 3Toll-Like Receptor 7TYRO3 protein, humanUbiquitins

Identifiers

PMID26085147
PMCPMC4524089
OpenAlexW1857453373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.